SCHEMBL4119074

SCHEMBL4119074

COc1cccc(C(=O)c2cc(Cl)ccc2F)c1OC

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.47
SMN1; SMN2 Q16637 4/20 0.47
KDM4E B2RXH2 4/20 0.47
ALDH1A1 P00352 4/20 0.47
RAB9A P51151 3/20 0.47
LMNA P02545 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
TP53 P04637 1/20 0.45
RORC P51449 2/20 0.44
RORB Q92753 2/20 0.44
NR1H2 P55055 1/20 0.44
KMT2A Q03164 3/20 0.43
MEN1 O00255 2/20 0.43
MAPK14 Q16539 1/20 0.43
KCNMA1 Q12791 1/20 0.43
HIF1A Q16665 1/20 0.43
GAA P10253 1/20 0.43
MRGPRX4 Q96LA9 1/20 0.43
HPGD P15428 2/20 0.42
MAPT P10636 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL635552 0.86 RECQL (0.56) NPC1SMN1; SMN2KDM4EALDH1A1RAB9A
SCHEMBL3586573 0.85 KDM4E (0.49) NPC1SMN1; SMN2KDM4EALDH1A1RAB9A
SCHEMBL3762150 0.82 RAB9A (0.55) NPC1SMN1; SMN2KDM4EALDH1A1RAB9A
SCHEMBL13502193 0.81 MRGPRX4 (0.46) NPC1SMN1; SMN2KDM4EALDH1A1RAB9A
SCHEMBL4122687 0.81 L3MBTL1 (0.44) NPC1SMN1; SMN2KDM4EALDH1A1RAB9A
SCHEMBL4110282 0.80 RAB9A (0.41) NPC1SMN1; SMN2KDM4EALDH1A1RAB9A
SCHEMBL5990108 0.80 NPC1 (0.53) NPC1SMN1; SMN2KDM4EALDH1A1RAB9A
SCHEMBL8176832 0.80 MAPK14 (0.58) NPC1SMN1; SMN2KDM4EALDH1A1RAB9A
SCHEMBL15870034 0.80 TUBB4A (0.55) LMNAMAPT
SCHEMBL8181985 0.80 CES2 (0.49) NPC1SMN1; SMN2KDM4EALDH1A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090181942-A1 TRICYCLIC COMPOUNDS DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-07-16 US disclosed
EP-1939205-A1 TRICYCLIC COMPOUND Daiichi Sankyo Company, Limited (JP) 2008-07-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181942-A1 TRICYCLIC COMPOUNDS FDFT1, COASY, HMGCR NPC1 187/4885SMN1; SMN2 4445/4885KDM4E 2123/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.